Cimicoxib

Overview

Cimicoxib (UR-8880) is an orally active, blood-brain barrier-permeable COX-2 inhibitor that also exerts targeted inhibition on CYP2D15 . It has an IC 50 of 66 nM against hCOX-2 , an IC 50 of 1.6 μM against canine CYP2D15 , and an IC 50 of 0.056 μM against feline CYP2D15 . By inhibiting the COX-2 pathway to reduce the production of thromboxane B2 and prostaglandin E2, Cimicoxib exerts antipyretic, anti-inflammatory and analgesic effects. Cimicoxib is metabolized by CYP2D15 to form demethyl-cimicoxib, undergoes glucuronidation via UDP-glucuronosyltransferases, and exhibits biphasic elimination kinetics in beagle dogs. Cimicoxib is widely used in studies of inflammatory diseases, osteoarthritis, and perioperative pain associated with orthopedic or soft tissue surgeries.

Application

Products | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Arthritis | Products > Disease Areas > Osteoarthritis | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > COX | Products > Signaling Pathways > Cytochrome P450

Product Information

• Catalog No.: HY-100516
• CAS No.: 265114-23-6
• Molecular Formula: C16H13ClFN3O3S
• Molecular Weight: 381.81
• Purity: 98.02%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Availability: In-stock

Source

Original product source